Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- MHLW Survey Finds Nearly 10% of Doctors Who Prescribe Prazaxa Are Unaware of Warnings in Blue Letter
December 28, 2012
- MHLW Compiling Database of Drug Approvals Overseas
December 28, 2012
- PMDA Review Period Reduced for Both Priority, Standard Products
December 28, 2012
- 2nd Abe Cabinet Inaugurated; Industry Awaits Decision on Perpetuation of Premium for New Drug Development
December 27, 2012
- MHLW Approves 23 Products Including Toviaz
December 26, 2012
- LDP to Finalize Tax Reform Outline for FY2013 by Late January
December 26, 2012
- OTC Switching of Life Style Disease Treatments on Different Level from that of Conventional Treatments: JMA Vice President Nakagawa
December 25, 2012
- MHLW to Establish a Venue for Discussions to Review Policies for OTC Switching of Lifestyle Disease Treatments
December 21, 2012
- Osaka’s Healthcare Plan Highlights Differences in Definition of “Frequent Deliveries”
December 21, 2012
- PAC Approves OTC Switching of Epadel
December 21, 2012
- CSIMC Recommends New Rules on Reducing Prices of Long-Listed Drugs
December 21, 2012
- MHLW to Revise and Consider Legislation of Ethical Guidelines for Clinical Research
December 20, 2012
- DPJ Loses Big, Nagatsuma Only Health Minister Veteran to Retain Seat
December 19, 2012
- Pharmaceutical Industry Welcomes Incoming Abe Administration
December 19, 2012
- MHLW Invites Applicants for Developing New Flu Vaccine Using Cell Culture Method Due to BIKEN Withdrawal
December 18, 2012
- PFSB Issues First Guidance on Quality Evaluation of Antibody Drugs
December 18, 2012
- Health Minister Mitsui Loses Seat in Lower House Election
December 18, 2012
- LDP Wins Landslide in Lower House Election, Social Security Bigwigs Reinstated
December 18, 2012
- 60% Rule Applied to 5 APIs in December Generic Listing
December 14, 2012
- Mr Sato of PFSB Stresses Need for MAH to Strengthen Ties, Communications with Overseas Drug Substance Manufacturers: PDA Japan Annual Meeting
December 14, 2012
ページ
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s FY2026 drug pricing reform is set to usher in a new phase for the generics market, effectively bringing an…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…